(Reuters) – CymaBay Therapeutics Inc mentioned its experimental lead drug met the primary purpose of decreasing episodes of gout in a mid-stage find out about.
The corporate mentioned the drug, arhalofenate, used to be proven to be secure and neatly tolerated.
Gout is a situation affecting joints and muscle tissue when the physique acts towards a construct-up of uric acid within the blood.
(Reporting by using Rosmi Shaji in Bengaluru; Modifying through Saumyadeb Chakrabarty)
<div id="proGrids10066"/>
<div id="crp_related" class="crp_related">Related Posts:
The corporate mentioned the drug, arhalofenate, used to be proven to be secure and neatly tolerated.
Gout is a situation affecting joints and muscle tissue when the physique acts towards a construct-up of uric acid within the blood.
(Reporting by using Rosmi Shaji in Bengaluru; Modifying through Saumyadeb Chakrabarty)
<div id="proGrids10066"/>
- CymaBay’s gout drug meets major intention in mid-stage February 24, 2015 Feb 24 (Reuters) - CymaBay Therapeutics Inc stated its experimental…
- CytRx most cancers drug displays promise in mid-stage learn… January 8, 2015 (Reuters) - CytRx Corp stated its most cancers drug used…
- Alkermes schizophrenia drug meets major intention in… January 7, 2015 Jan 7 (Reuters) - Alkermes %said itsexperimental drug to deal…
- UPDATE 1-Alkermes schizophrenia drug meets major purpose in… January 7, 2015 (Provides important points, inventory motion) (Provides important points, share transfer)Jan…
- FDA seeks extra security information on Antares testosterone January 13, 2015 Jan thirteen (Reuters) - Antares Pharma Inc stated the U.S.…
via Smart Health Shop Forum http://ift.tt/1zcAc1H
No comments:
Post a Comment